95222 Federal Register / Vol. 89, No. 231 / Monday, December 2, 2024 / Notices 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2024–N–4085 for ‘‘Advancing Smoking 

Cessation: Food and Drug 

Administration and National Institutes 

of Health Priorities.’’ Received 

comments, those filed in a timely 

manner (see ADDRESSES), will be placed 

in the docket and, except for those 

submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://

www.govinfo.gov/content/pkg/FR-2015- 

09-18/pdf/2015-23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852, 240–402–7500. 

FOR FURTHER INFORMATION CONTACT: 

Laura Chilaka, Center for Tobacco 

Products, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Silver Spring, MD 20993, 877– 

287–1373, TobaccoCessation@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: On 

September 23, 2024, FDA published in 

the Federal Register a notice 

announcing a public meeting entitled 

‘‘Advancing Smoking Cessation: Food 

and Drug Administration and National 

Institutes of Health Priorities.’’ Jointly 

convened by FDA and the National 

Institutes of Health, this public meeting 

addressed the need for novel smoking 

cessation products to help individuals 

of all ages, including underserved and 

vulnerable populations, stop smoking. 

Interested persons were originally 

given until November 21, 2024, to 

submit comments on the public 

meeting. 

FDA has received requests for 

additional time in submitting 

comments. Due to the significant 

interest in the topic and to allow 

interested parties time to review the 

meeting transcript and recording, FDA 

has reopened the comment period until 

December 20, 2024. 

Dated: November 25, 2024. 

P. Ritu Nalubola, 

Associate Commissioner for Policy. 

[FR Doc. 2024–28205 Filed 11–29–24; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Recharter for the National Advisory 

Council on Nurse Education and 

Practice 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, HHS 

is hereby giving notice that the National 

Advisory Council on Nurse Education 

and Practice (NACNEP or Council) is 

rechartered. 

DATES: The effective date of the 

recharter is November 30, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Justin Bala-Hampton, Bureau of Health 

Workforce, HRSA, 5600 Fishers Lane, 

Rockville, Maryland 20857; 301–443– 

2765 or BHWNACNEP@hrsa.gov. 

SUPPLEMENTARY INFORMATION: NACNEP 

provides advice and recommendations 

to the Secretary of HHS and Congress on 

policy matters and the preparation of 

general regulations concerning activities 

under title VIII of the Public Health 

Service Act, including the range of 

issues relating to the nurse workforce, 

education, and practice improvement. 

NACNEP also prepares and submits an 

annual report to the Secretary of HHS 

and Congress describing its activities, 

including NACNEP’s findings and 

recommendations concerning activities 

under title VIII, as required by the 

Public Health Service Act. The recharter 

of NACNEP was approved on October 

31, 2024. The filing date for the 

NACNEP recharter is November 30, 

2024. The recharter of NACNEP gives 

authorization for the Council to operate 

until November 30, 2026. 

A copy of the NACNEP charter is 

available on the NACNEP website at 

https://www.hrsa.gov/advisory

committees/nursing/about.html. A copy 

of the charter can also be obtained by 

accessing the FACA database that is 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 231 / Monday, December 2, 2024 / Notices 95223 

maintained by the Committee 

Management Secretariat under the 

General Services Administration. The 

website address for the FACA database 

is https://www.facadatabase.gov/. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–28087 Filed 11–29–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Infant and Maternal Mortality 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 

Committee on Infant and Maternal 

Mortality (ACIMM or Committee) has 

scheduled a public meeting. Information 

about ACIMM and the agenda for this 

meeting can be found on the ACIMM 

website at https://www.hrsa.gov/ 

advisory-committees/infant-mortality/ 

index.html. 

DATES: January 7, 2025, from 12:00 p.m. 

to 5:00 p.m. Eastern Time and January 

8, 2025, from 12:00 p.m. to 5:00 p.m. 

Eastern Time. 

ADDRESSES: This meeting will be held 

by webinar. The webinar link and login information will be available at the 

ACIMM website before the meeting: 

https://www.hrsa.gov/advisorycommittees/infant-mortality/index.html. 

FOR FURTHER INFORMATION CONTACT: 

Vanessa Lee, MPH, Designated Federal 

Official, Maternal and Child Health 

Bureau, HRSA, 5600 Fishers Lane, 

Rockville, Maryland, 20857; 301–443– 

0543; or SACIM@hrsa.gov. 

SUPPLEMENTARY INFORMATION: ACIMM is 

authorized by section 222 of the Public 

Health Service Act (42 U.S.C. 217a), as 

amended. The Committee is governed 

by provisions of the Federal Advisory 

Committee Act (5 U.S.C. Chapter 10), as 

amended. 

ACIMM advises the Secretary of 

Health and Human Services on 

department activities, partnerships, 

policies, and programs directed at 

reducing infant mortality, maternal 

mortality, and severe maternal 

morbidity and improving the health 

status of infants and women before, 

during, and after pregnancy. The 

Committee provides advice on how to 

coordinate federal, state, local, tribal, 

and territorial governmental efforts 

designed to improve infant mortality; 

related adverse birth outcomes; and 

maternal health; as well as influence 

similar efforts in the private and 

voluntary sectors. The Committee 

provides guidance and 

recommendations on the policies, 

programs, and resources required to 

address the disparities and inequities in 

infant mortality; related adverse birth 

outcomes and maternal health 

outcomes, including maternal mortality 

and severe maternal morbidity. With its 

focus on underlying causes of the 

disparities and inequities seen in birth 

outcomes for women and infants, the 

Committee advises the Secretary of 

Health and Human Services on the 

health, social, economic, and 

environmental factors contributing to 

the inequities and proposes structural, 

policy, and/or systems level changes. 

The agenda for the January 7–8, 2025, 

meeting is being finalized and may 

include the following topics: federal 

updates; Committee operations updates; 

discussion of draft recommendations for 

the Secretary on achieving optimal 

maternal health and overall birth 

outcomes for underserved populations, 

including Black/African-American 

families; and a vote on whether to send 

the draft recommendations forward. 

Agenda items are subject to change as 

priorities dictate. Refer to the ACIMM 

website listed above for any updated 

information concerning the meeting. 

Members of the public will have the 

opportunity to provide written or oral 

comments. Public participants may 

submit written statements in advance of 

the scheduled meeting by emailing 

SACIM@hrsa.gov. Oral comments will 

be presented in the order they are 

requested and may be limited as time 

allows. Requests to submit a written 

statement or make oral comments to 

ACIMM should be sent to Vanessa Lee, 

Designated Federal Official, using the 

email address above, at least 3 business 

days prior to the meeting. 

Individuals who plan to attend and 

need special assistance or another 

reasonable accommodation should 

notify Vanessa Lee at the contact 

information listed above at least 10 

business days prior to the meeting. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–28155 Filed 11–29–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Advisory Committee on 

Minority Health 

AGENCY: Office of Minority Health, 

Office of the Secretary, U.S. Department 

of Health and Human Services. 

ACTION: Notice of meeting. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that the Advisory Committee on 

Minority Health (ACMH) will hold a 

meeting conducted as a webcast on 

December 16, 2024. This virtual meeting 

will be open to the public. Registration 

is required for the public to attend the 

meeting, provide comment, and/or 

distribute material(s) to ACMH 

members. 

DATES: The virtual ACMH meeting will 

be held on December 16, 2024, from 2 

p.m. to 3:30 p.m. eastern standard time 

(EST). If the Committee completes its 

work before 3:30 p.m. EST, the meeting 

will adjourn early. 

ADDRESSES: The meeting will be held 

virtually and will be accessible by 

webcast. Instructions regarding webcast 

access and providing written public 

comments will be given after meeting 

registration occurs. 

Any individual who wishes to 

participate in the virtual meeting should 

register using the Zoom registration link 

provided below by 5 p.m. EST on 

December 12, 2024. Instructions 

regarding participating in the call and 

providing written or verbal public 

comments will be provided after 

meeting registration occurs. Information 

about the meeting will be posted on the 

HHS Office of Minority Health (OMH) 

website: www.minorityhealth.hhs.gov. 

Information about ACMH activities can 

be found on the OMH website under the 

heading About OMH, Committees and 

Working Groups. 

FOR FURTHER INFORMATION CONTACT: 

Violet Woo, Designated Federal Officer, 

Advisory Committee on Minority 

Health, OMH, HHS, Tower Building, 

1101 Wootton Parkway, Suite 100, 

Rockville, Maryland 20852. Phone: 240– 

453–6816; email: OMH-ACMH@hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with Public Law 105–392, 

the ACMH was established to provide 

advice to the Deputy Assistant Secretary 

for Minority Health on the development 

of goals and program activities related to 

OMH’s duties. 

The topics to be discussed during the 

virtual meeting include finalizing: (1) 


ddrumheller on DSK120RN23PROD with NOTICES1